Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice

PURPOSE: Non-bismuth concomitant quadruple therapy is commonly administered in Taiwan, achieving an acceptable efficacy as a first-line anti-Helicobacter pylori treatment. This study compared the eradication rates between esomeprazole- and lansoprazole-based non-bismuth concomitant quadruple therapy...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Infect Drug Resist
Hauptverfasser: Hung, Kuo-Tung, Yang, Shih-Cheng, Wu, Cheng-Kun, Wang, Hsing-Ming, Yao, Chih-Chien, Liang, Chih-Ming, Tai, Wei-Chen, Wu, Keng-Liang, Kuo, Yuan-Hung, Lee, Chen-Hsiang, Chuah, Seng-Kee
Format: Artigo
Sprache:Inglês
Veröffentlicht: Dove 2021
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8007608/
https://ncbi.nlm.nih.gov/pubmed/33790594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IDR.S304711
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge